We conclude that administration of these cold-recombinant vaccine viruses to older adults with chronic diseases was safe, but that serum antibody response rates were lower than those achieved with subsequently administered inactivated influenza virus vaccine given parenterally. However, the higher seroconversion rates attained by using the inactivated trivalent influenza virus vaccine do not necessarily mean that it is more efficacious in preventing infection or severe illness or both due to natural wild-type influenza A virus.
Before each respiratory disease season, it is recommended that populations at high risk for complications resulting from influenza virus infection be immunized against the prevalent strains of influenza viruses (11, 12) . The purpose of this immunization is to reduce mortality and morbidity from influenza illness and pneumonia (either primary viral or secondary bacterial pneumonia). Among those recommended to receive influenza vaccine are persons over the age of 65 years and patients with chronic lung, heart, or metabolic disease. Despite a documented need for influenza immunization in these populations, compliance may be low and the efficacy of inactivated influenza virus vaccine may be lower in the elderly than in younger persons (26) . The fourfold rate of serologic response to inactivated virus parenteral vaccines has ranged from 70 to 90%, and in certain elderly subpopulations the response rate has been as low as 21% (4, 8, 9, 16-18, 21, 26, 28, 31) . Previous influenza virus vaccination appears to decrease the rate of serologic response to subsequent vaccination as well (8) .
Intranasally administered live-attenuated, cold-recombinant (CR) influenza A virus vaccines offer a potentially more desirable and effective approach to immunization against influenza A virus infection. CR virus vaccines do not require parenteral injection and offer the theoretical advantage of stimulating secretory immunoglobulin A (IgA) antibody production at the natural portal of entry (31) . Neutral- izing IgA antibody and, to a lesser extent, IgG antibody are present in nasal wash specimens taken from volunteers who are resistant to challenge with influenza A. The antihemagglutinin serum IgA antibody level may correlate with the production of secretory IgA in the respiratory tract, perhaps due to the escape of locally produced IgA antibody from the nasal mucosa into the systemic circulation (10, 24) . * Corresponding author.
Clements et al. (14) reported that protection against wildtype virus challenge in young adults was greater after vaccination with influenza A/Washington/897/80 (H3N2) (CR48) virus than after parenteral inactivated trivalent influenza virus vaccine. The CR virus vaccine also reduced the titer of wild-type virus shed in respiratory secretions compared with the inactivated virus vaccine.
Worsening of chronic airways disease is a potential hazard with widespread use of live-attenuated virus vaccine. This has not, however, been clinically apparent in previously reported series in which persons with chronic bronchitis, asthma, or chronic obstructive pulmonary disease (COPD) were vaccinated with other live-attenuated or CR virus strains (1, 19, 22 Hemagglutination inhibition (HAI) antibodies were measured by using whole virus homologous to the two CR virus vaccine strains in a standard microtiter assay (32) .
Each CR vaccine virus strain was grown in the allantoic cavity of eggs, and the HA was extracted and purified by previously described methods (27) , including nonionic detergent solubilization, density gradient centrifugation, and affinity chromatography. A one-step enzyme-linked immunosorbent assay (ELISA) previously described by Murphy et al. (24, 25) inactivated influenza virus vaccine at some time in previous years, one had not, and this information was not known for the remaining eight vaccinees. Of the CR48 (H3N2) vaccinees, 14 had received inactivated influenza virus vaccine at some time in previous years, 11 had not, and this information was not known for the remaining 2 vaccinees. Postvaccination follow-up for possible CR vaccine virusrelated complications. Morbidity during the first 7 days postvaccination occurred in five CR virus vaccinees, who developed upper-respiratory-tract symptoms (e.g., rhinitis and sore throat). Only one of these five persons had become infected with the vaccine virus. Conjunctivitis developed in two CR vaccinees, neither of whom had become infected with the vaccine virus; viral cultures of conjunctival swab specimens did not yield a virus. One CR virus vaccinee required hospitalization for a supraventricular tachycardia. He had not become infected with vaccine virus and had a history of supraventricular arrhythmias predating vaccination. A CR48 (H3N2) vaccinee who had developed a fourfold rise in IgG antibody titer and who shed vaccine virus on days 2 and 3 postvaccination developed an influenzalike clinical illness 10 months after live-attenuated virus vaccination, and wild-type influenza A virus H3N2 was isolated from a nasal swab culture at that time.
None of the vaccinees developed increased dyspnea postvaccination. Of the 21 CR48 (H3N2) vaccinees who underwent PFT, 2 experienced a worsening in FEV1/FVC from one category of airflow obstruction to another and 5 experienced an improvement in FEV1/FVC from one category to another ( (Table 5 ; Mann-Whitney test, z = -2.1, P = 0.03 and z = -2.2., P = 0.03, respectively).
As measured by IgG ELISA, significantly fewer CR37 (HiN1) virus vaccinees manifested a fourfold antibody response to Hi than did inactivated virus vaccinees (Table 4 ; P < 0.001, Fisher's exact test, one-tailed), and the mean fold increase in IgG antibody to Hi was significantly higher after inactivated trivalent influenza virus vaccine than after liveattenuated virus vaccine (Table 5 ; Mann-Whitney test, z = -2.6, P = 0.011). Although a larger proportion of vaccinees seroresponded to CR48 virus than to CR37 virus, CR48 (H3N2) virus vaccinees manifested fourfold increases in IgG antibody (all seroresponders received the 107 7 TCID50S of virus) significantly less often than did recipients of inactivated virus vaccine (Table 4 ; x2 = 8.9, P < 0.01). The mean fold increase in IgG antibody to H3 HA was significantly greater after inactivated virus vaccine (Table 5 ; MannWhitney test, z = -2.5, P = 0.01).
As measured by IgA ELISA, 1 (inoculum of 106 1 TCID50s) of may be a low estimate of the proportion of infected individuals, because additional vaccinees may have developed isolated rises in nasal wash secretory IgA antibody titer without other evidence of vaccine virus infection. Fourfold rises in serum HAI, IgG, or IgA antibody titer or in all three among the 18 recipients of the inactivated influenza virus vaccine were more frequent to both Hi (P = 0.002, Fisher's exact test, one-tailed) and H3 HA (X2 = 8.52, P = 0.003) than they were among the CR virus vaccinees (Table 4) . Seroresponse as a function of prevaccination antibody titer. Because prevaccination antibody titer may have influenced response to the vaccines, we compared reciprocal prevaccination antibody titers as a function of subsequent seroresponse to vaccination. Prevaccination HAI antibody titer did not appear to influence HAI antibody response to live-attenuated virus vaccine; reciprocal geometric mean HAI titers of nonseroresponders compared with those of seroresponders to each of the live-attenuated virus vaccines were not significantly different. However, prevaccination reciprocal geometric mean HAI titer to H3 among the nonseroresponders who received inactivated virus vaccine was significantly higher than among seroresponders (47.0 versus 21.8; z = 2.56, P = 0.01, Mann-Whitney test). Among CR48 virus vaccine recipients, the prevaccination reciprocal IgG ELISA geometric mean titer of nonseroresponders was higher than that of seroresponders (2,011 versus 319; z = 2.37, P = 0.017). Among the inactivated virus vaccine recipients, high ELISA IgG antibody was correlated with absence of ELISA antibody response (nonseroresponders versus seroresponders to Hi antigen, 7,071 versus 2,530, z = 2.22, P = 0.025; H3 antigen, 7,113 versus 475, z = 2.55, P = 0.011, Mann-Whitney test). No significant differences were found in prevaccination reciprocal geometric mean IgA ELISA titers comparing the nonseroresponders and seroresponders.
No significant differences occurred in prevaccination reciprocal geometric mean HAI, IgG, or IgA antibody titers between nonseroresponders to CR37 (HlNl) virus and nonseroresponders to the Hi antigen of the inactivated virus vaccine or between nonseroresponders to CR48 (H3N2) virus and the H3 antigen of inactivated virus vaccine. In addition, there were no significant differences by the same measures among seroresponders to CR48 (H3N2) virus and the H3 antigen of the inactivated virus vaccine.
Effect of history of influenza virus vaccination on seroresponse to CR48 (H3N2) virus vaccine. Of the 27 CR48 (H3N2) virus vaccine recipients, 25 were able to give a vaccine history that was believed to be reliable before this study. Fourteen recipients had been vaccinated in a previous year with inactivated influenza virus vaccine, and 11 had never been vaccinated for influenza. Of the 14 vaccine recipients with a history of inactivated virus vaccination, 5 became infected with the live-attenuated CR48 (H3N2) vaccine virus, and 9 did not. This was not significantly different from the 7 of the 11 who became infected with vaccine virus and gave a history of no previous influenza vaccination. (20) . When detected, the changes occurred at both 3 and 10 days postvaccination. The same studies have not been done in patients with underlying COPD.
Parenteral administration of inactivated trivalent influenza virus vaccine 5 to 12 months after CR virus vaccination resulted in significantly higher rates of fourfold serum antibody increases compared with the rates of fourfold antibody increases after the intranasal administration of CR vaccine viruses. It is possible that the response rates to the inactivated virus vaccine were enhanced by the patients' exposure to the CR vaccine virus within the previous year. However, the rates of seroresponse to inactivated virus vaccine in our patients were similar to those reported in the literature for this type of noninstitutionalized older adult (4, 8, 9, 16-18, 21, 26, 28, 29, 31) . Alternatively, it is likely that the preexisting experience with other influenza A virus serotypes prevented infection with CR virus but did not prevent a serologic response to the inactivated virus vaccine.
As in seronegative children (5, 6) , the CR48 (H3N2) vaccine virus was more infectious in our older adult population than was the CR37 (H1N1) vaccine virus. This may reflect an actual difference in the infectivity of the two viruses. No definite explanation for this difference is available, since the infectivity of these two vaccine viruses is determined theoretically by the six genes provided by the common parent virus strain (influenza A/Ann Arbor/6/60).
Most previous studies of older, seropositive adults report the serologic response to influenza A vaccine in terms of the HAI antibody titer. Our trivalent virus vaccine recipients demonstrated an HAI response rate comparable to that seen in other series (9, 21 (14) found a higher rate of nasal wash secretory IgA antibody rises among seronegative young adults who received intranasal CR48 (H3N2) virus compared with the response after parenteral administration of inactivated virus vaccine (69 versus 31%). For these reasons, determination of nasal wash IgA antibody levels in our patients will provide further important information regarding the local immune response to CR virus vaccine and may increase the total number of infected vaccinees detected.
The higher seroconversion rates attained by using the inactivated trivalent influenza virus vaccine do not necessarily mean that it is more efficacious in preventing infection or severe illness or both due to natural wild-type influenza A virus. Differences in the stimulation of secretory humoral immunity and of cellular immunity (e.g., cytotoxic T cells and enhanced lymphokine production) produced by the various vaccines may be more important determinants of protection against natural challenge and recovery from infection. Furthermore, response to live-attenuated influenza A virus vaccine may separate vaccinees with previous influenza A virus experience into two groups, those who are susceptible to wild-type influenza A virus infection and those who are already immune to natural challenge. Perhaps protection from infection by CR virus vaccination correlates with protection from naturally acquired wild-type influenza A virus. If infection caused by CR virus vaccine induces protection against wild-type influenza A virus and if adults who fail to become infected after CR virus vaccination are immune to naturally acquired influenza A virus, CR virus vaccine may have superior efficacy when compared with inactivated virus vaccine. Our safety and antigenicity tests provide the foundation for further studies with these promising live-attenuated influenza virus vaccines.
